1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
(
- Contribution to journal › Article
-
Mark
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
(
- Contribution to journal › Article
- 2022
-
Mark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
(
- Contribution to journal › Article
- 2018
-
Mark
Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range
(
- Contribution to journal › Article
-
Mark
Combination of phage and Gram-positive bacterial display of human antibody repertoires enables isolation of functional high affinity binders
(
- Contribution to journal › Article
- 2016
-
Mark
Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach.
(
- Contribution to journal › Article
-
Mark
Generation and analyses of human synthetic antibody libraries and their application for protein microarrays
(
- Contribution to journal › Article
- 2015
-
Mark
Recombinant Antibodies – Tools for building proteomic platforms
2015)(
- Thesis › Doctoral thesis (compilation)
-
Mark
A microarray-based reaction rate analysis platform. Is there evidence of validity?
(
- Contribution to journal › Letter
-
Mark
Development of Phage-Based Antibody Fragment Reagents for Affinity Enrichment of Bacterial Immunoglobulin G Binding Proteins.
(
- Contribution to journal › Article